US Executive Officer Management Changes SEC — April 29, 2026

USA Executive & Director Changes

30 high priority30 total filings analysed

Executive Summary

Across 30 SEC filings on USA Executive & Director Changes dated April 29, 2026, the dominant theme is neutral transitions with 70%+ involving retirements, non-re-elections, or planned departures without disagreements (e.g., Tri-State CAO, Sprinklr directors, Vertex CFO nominee), signaling board refreshments amid stability. Positive appointments and planned successions in banking (Hawthorn Bancshares, City Holding, First Mid Bancshares, Kinsale) and biotech/tech (Olema Pharma, Rambus CFO) highlight strategic enhancements, comprising 25% of filings. Financial enriched data shows strong revenue growth where reported (Anika Therapeutics +13% YoY to $29.6M, Plexus +19% YoY to $1.164B record, Telos Q1 prelims above March guide), but mixed margins (Anika gross +810 bps to 64.2%, Plexus GAAP operating to 4.1-4.5% Q3 guide down from 5.3%). High materiality events (9/10) include Telos CEO medical leave with strong prelims, Southern Copper CEO passing, Anika $15M repurchase amid director exits, and First Mid $6.5B asset growth under transition. Capital allocation leans shareholder-friendly (Anika repurchase at $10.76 avg, AutoNation/Fastenal equity plans approved >90%). Portfolio-level: Low disruption risk (no ops impacts noted), outperformance in revenue growers vs. neutral peers, watch Q2 catalysts like Plexus FCF $50-75M FY26 target.

Tracking the trend? Catch up on the prior US Executive Officer Management Changes SEC digest from April 22, 2026.

Investment Signals(12)

  • Q1 revenue +13% YoY to $29.6M (OEM +14% to $17M, Commercial +12% to $12.6M), gross margin +810 bps to 64.2%, $15M 10b5-1 repurchase at $10.76 avg, FY26 guide unchanged 1-9% growth

  • Q2 FY26 record revenue +19% YoY/+9% QoQ to $1.164B, non-GAAP EPS $2.05, $355M wins, Q3 guide $1.2-1.25B (+5% seq mid), FY26 FCF $50-75M despite customer concentration to 54%

  • Telos Corp(BULLISH)

    Q1 prelim revenue/Adj EBITDA above high-end March 16 guide despite CEO medical leave, FY outlook reaffirm on May 11 call, interim leadership continuity

  • Appt Grant Burcham (34yr exec exp, Entrepreneur of Year) as Class III director to support growth, positive CEO endorsement

  • Elected B. Scott Raynes (healthcare CEO exp) as Class II director, board expands to 12, $6.8B assets/96 branches

  • Rambus Inc(BULLISH)

    Appt Sumeet Gagneja (AMD/WD/Xilinx CFO exp in semis/AI) as SVP/CFO effective Apr 29, CEO highlights scaling expertise

  • Planned CEO transition Jul 1 (Pres Smith succeeds, assets +232% to $9.3B since 2016), continuity via Exec Chairman Dively

  • Appt Prakash Raman PhD (Novartis BD head, InduPro CEO) to board, supports Phase 3 OPERA-01 data fall 2026

  • Realignment promo Salmaan Allibhai to EVP Chief Analytics/Tech Officer, enhances data-driven decisions post CIO retirement

  • AutoNation(BULLISH)

    2026 AGM all mgmt proposals pass >90% (9 directors elected, equity plan 1.275M new shares +883k prior, Say-on-Pay 94% for)

  • Solésence(BULLISH)

    Appt Marc James (capital mkts exp) independent director to Audit/Comp/Nom, supports Transform & Transcend strategy

  • Fastenal(BULLISH)

    AGM approves Employee RSU and Non-Employee Director plans, no director changes

Risk Flags(10)

Opportunities(10)

Sector Themes(6)

  • Banking Leadership Bolstering(BULLISH SECTOR)

    5/7 bank filings (Hawthorn, City Holding x2, First Mid, Kinsale) feature positive appointments/promos/transitions vs neutral peers, assets growth (First Mid +232% YoY), implying M&A/growth conviction

  • Biotech/Health Board Refresh

    7/30 (Anika, BridgeBio, Olema, MapLight, TriSalus, Vertex, City Raynes healthcare) show director/CEO changes, revenue/margins strong where fin data (Anika +13% rev/+810bps gross), pipeline catalysts fall 2026 [MIXED, WATCH PIPELINE]

  • Tech/Software Neutral Turnover(NEUTRAL SECTOR)

    High volume neutral CTO/dir exits (Yelp CTO Jun30, Sprinklr 2 dirs, Telos CEO leave but prelim beat), no fin declines but monitor ops disruption

  • Planned Retirements Dominant(STABILITY THEME)

    18/30 filings (60%) retirements/non-reelects with successors/consulting (Tri-State Dec26, Nextpower Jul17, Yelp Jun30), no disagreements, low materiality avg 5/10

  • Capital Allocation Supportive(BULLISH RETURNS)

    Shareholder plans approved (AutoNation 2.1M shares >90%, Fastenal RSU plans), Anika $15M repurchase amid severance, Plexus FCF guide up

  • Margin Trends Mixed in Reporters(GROWTH OUTLIERS)

    3/3 fin reporters: Anika expansion +810bps, Plexus Q3 contraction -80bps guide, Telos Adj EBITDA beat; avg revenue +13% YoY outliers vs neutral filings

Watch List(8)

Filing Analyses(30)
Anika Therapeutics, Inc.8-Kmixedmateriality 9/10

29-04-2026

Anika Therapeutics reported first quarter 2026 revenue of $29.6 million, up 13% year-over-year, driven by 14% OEM Channel growth to $17.0 million and 12% Commercial Channel growth to $12.6 million, alongside gross margin expansion to 64.2% from 56.1%. Adjusted EBITDA rose to $4.3 million from $0.1 million, reflecting operational improvements, however GAAP loss from continuing operations widened to $5.1 million ($0.37 per diluted share) from approximately $4.0 million due to $4.9 million in one-time severance costs pushing operating expenses to $24.5 million. The company completed a $15 million 10b5-1 share repurchase at an average price of $10.76 per share, provided unchanged FY2026 guidance implying 1-9% total revenue growth, and announced two directors stepping down at the 2026 Annual Meeting.

  • ·FY2026 guidance: Total revenue $114-$122.5M (1-9% YoY growth), Commercial Channel $53-$58M (10-20% growth), OEM Channel $61-$64.5M (flat to modestly lower), Adjusted EBITDA 5-10% of revenue
  • ·Share repurchase completed April 10, 2026, at average $10.76 per share
  • ·Directors Dr. Glenn Larsen and Bill Jellison to step down at 2026 Annual Meeting, not due to disagreements
Tri-State Generation & Transmission Association, Inc.8-Kneutralmateriality 4/10

29-04-2026

On April 27, 2026, Tri-State Generation and Transmission Association, Inc. received notice from its Chief Administrative Officer and Chief Human Resources Officer, Elda de la Peña, that she intends to retire in December 2026 after more than 29 years of service. Tri-State plans to initiate a search for a successor. No immediate disruption to operations is indicated.

  • ·Tri-State's principal executive offices: 1100 W. 116th Avenue, Westminster, Colorado 80234
  • ·Telephone: (303) 452-6111
  • ·Filing date: April 29, 2026
AUTONATION, INC.8-Kpositivemateriality 6/10

29-04-2026

At AutoNation, Inc.'s 2026 Annual Meeting on April 28, 2026, stockholders elected all nine director nominees, ratified KPMG LLP as the independent auditor for 2026, approved executive compensation on an advisory basis, and approved the 2026 Employee Equity and Incentive Plan authorizing up to 1,275,000 new shares plus 883,316 shares from the prior plan. Two stockholder proposals—an independent Board chairman and a GHG report—were overwhelmingly rejected. All management proposals passed with strong majorities exceeding 90% support in most cases.

  • ·Proposal 1 (Director Elections): Votes ranged from 28,311,470 For (Jacqueline A. Travisano) to 29,278,480 For (Claire Bennett), with Against/Abstain minimal.
  • ·Proposal 2 (Auditor Ratification): 31,482,534 For, 454,816 Against.
  • ·Proposal 3 (Say-on-Pay): 27,776,185 For, 1,616,323 Against.
  • ·Proposal 4 (2026 Plan): 29,066,751 For, 330,782 Against.
  • ·Proposal 5 (Independent Chairman): 1,799,833 For, 27,561,657 Against.
  • ·Proposal 6 (GHG Report): 4,387,899 For, 24,369,831 Against.
  • ·2026 Plan approved by Board on January 28, 2026, subject to stockholder vote.
HAWTHORN BANCSHARES, INC.8-Kpositivemateriality 6/10

29-04-2026

Hawthorn Bancshares, Inc. (NASDAQ: HWBK) announced the appointment of Grant Burcham as a Class III director to its Board of Directors and that of subsidiary Hawthorn Bank, effective April 29, 2026, with his term expiring at the 2028 annual meeting of shareholders. Burcham brings over three decades of executive experience, including 34 years at Missouri Bank & Trust as Chairman and CEO, leading its growth before its 2016 sale to BOK Financial, and current roles as Managing Partner of Big Bear Ventures and Chairman of CyTek Corporation. CEO Brent Giles highlighted Burcham's entrepreneurial vision and operational discipline as key strengths for supporting the company's growth.

  • ·Burcham acquired CyTek in 2021 and transformed it into a fast-growing technology company.
  • ·Burcham recognized as Ernst & Young’s Entrepreneur of the Year and named to Kansas City Business Journal’s Power 100.
  • ·Hawthorn Bank has served families and businesses for more than 160 years with locations in Kansas City metro, Jefferson City, Columbia, Springfield, and Clinton.
First American Financial Corp8-Kneutralmateriality 5/10

29-04-2026

On April 29, 2026, the Board of Directors of First American Financial Corporation and Executive Chairman Dennis J. Gilmore mutually agreed to cancel all outstanding unvested restricted stock units (RSUs) and performance-based restricted stock units (PRSUs) granted to Mr. Gilmore on June 20, 2025. The cancellation was entirely unvested and voluntary on Mr. Gilmore's part, with no exchange for other equity or cash compensation. The form of RSU and PRSU Cancellation Agreement is filed as Exhibit 10.1.

BridgeBio Oncology Therapeutics, Inc.8-Kneutralmateriality 7/10

29-04-2026

Eli Wallace, Ph.D. resigned from the Board of Directors as a Class III director, President, and CEO, effective April 20, 2026, and was succeeded by Pedro J. Beltran, Ph.D. in these roles. On April 27, 2026, the Company entered a 12-month consulting agreement with Dr. Wallace, effective retroactively from April 21, 2026, under which his sole compensation is the continued vesting of outstanding equity awards, subject to service through vesting dates. Dr. Wallace is also entitled to Tier 1 officer severance benefits pursuant to the Executive Severance Plan and a Separation Agreement dated April 27, 2026.

  • ·Consulting Agreement to be filed as exhibit to Q2 2026 10-Q.
  • ·Executive Severance Plan filed as Exhibit 10.23 to August 12, 2025 8-K.
  • ·Stock options exercisable until earliest of 2 years post-termination or original expiration.
Sprinklr, Inc.8-Kneutralmateriality 6/10

29-04-2026

Sprinklr, Inc. disclosed that Class II directors Yvette Kanouff and Neeraj Agrawal notified the Board on April 23, 2026, that they will not stand for re-election at the 2026 Annual Meeting and will retire upon term expiration, with no disagreements on company matters. The Board approved reducing its size from nine to seven directors effective at the Annual Meeting. Stephen M. Ward, Jr. will join the Audit Committee and Kevin Haverty the Nominating and Corporate Governance Committee at that time.

  • ·Notifications received April 23, 2026; filing dated April 29, 2026.
  • ·Class A Common Stock trades as CXM on NYSE.
FASTENAL CO8-Kneutralmateriality 4/10

29-04-2026

On April 23, 2026, Fastenal Company held its annual meeting of shareholders in Winona, Minnesota, where shareholders approved the Fastenal Company Employee Restricted Stock Unit Plan and the Fastenal Company Non-Employee Director Stock and Restricted Stock Unit Plan. Descriptions of these plans are in the definitive Proxy Statement, with full texts filed as Exhibits 10.1 and 10.2. No other significant outcomes or changes in directors/officers were reported.

  • ·Annual meeting held in Winona, Minnesota
  • ·Form 8-K filed on April 29, 2026
  • ·Securities: Common stock, par value $0.01 per share (FAST on Nasdaq)
VERTEX PHARMACEUTICALS INC / MA8-Kneutralmateriality 4/10

29-04-2026

On April 28, 2026, Suketu Upadhyay informed the Vertex Pharmaceuticals board that he will not stand for re-election at the 2026 Annual Meeting due to scheduling conflicts from his new role as CFO of Incyte Corporation, with no disagreement on company matters. He will continue serving until the meeting, after which the board size will reduce to ten members. Proxy materials have been amended to remove him as a nominee, while other nominees and prior votes remain valid.

  • ·Proxy materials deemed amended to remove Mr. Upadhyay as nominee; Company's slate of nominees otherwise unchanged.
  • ·Previously voted proxies remain valid except with respect to Mr. Upadhyay.
CITY HOLDING CO8-Kpositivemateriality 6/10

29-04-2026

Shareholders of City Holding Company (NASDAQ: CHCO) elected B. Scott Raynes to its Board of Directors as a Class II director for a two-year term at the Annual Meeting on April 29, 2026, expanding the board from 11 to 12 members. Raynes, current President and CEO of Marshall Health Network, brings extensive executive experience in healthcare systems including prior roles at Southeast Georgia Health System, Baptist Hospitals, Inc., and others. City Holding Company is a $6.8 billion bank holding company and parent of City National Bank, which operates 96 branches across four states.

  • ·Raynes holds a BA from West Virginia Institute of Technology, Master’s in Higher Education and Counseling from Morehead State University, and MBA with Healthcare specialization from West Virginia University.
  • ·Raynes previously served as President and CEO of Southeast Georgia Health System (Jan 2022–Feb 2025), President of Baptist Hospitals, Inc. (Aug 2013–Dec 2022), and other healthcare leadership roles.
Starco Brands, Inc.8-Kneutralmateriality 3/10

29-04-2026

On April 25, 2026, Bharat Vasan notified the Board of Directors of Starco Brands, Inc. that he resigns from the Board, effective April 27, 2026. Mr. Vasan’s departure is not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. The Board thanked Mr. Vasan for his contributions during his service.

  • ·Filing date: April 29, 2026; Date of earliest event reported: April 28, 2026
  • ·Resignation letter filed as Exhibit 17.1
  • ·Company trades as STCB on OTC Markets Group OTCQB tier
TELOS CORP8-Kmixedmateriality 8/10

29-04-2026

Telos Corporation announced that President, CEO, and Chairman John B. Wood is taking a medical leave of absence of uncertain duration, with no anticipated material disruption to operations; interim CEO duties are shared by Mark Griffin, Mark Bendza, and Hutch Robbins under Board oversight, while Fred Schaufeld was appointed interim Chairman. The company expects first-quarter revenue and Adjusted EBITDA above the high end of guidance provided on March 16, 2026, and plans to reaffirm its full-year outlook on the May 11, 2026 earnings call. This pre-announcement provides positive preliminary financial signals amid leadership transition uncertainty.

  • ·Event date: April 28, 2026
  • ·Filing date: April 29, 2026
  • ·Guidance reference date: March 16, 2026
  • ·Upcoming earnings call: May 11, 2026
  • ·Item 2.02 information furnished, not filed, per SEC rules
MapLight Therapeutics, Inc.8-Kneutralmateriality 6/10

29-04-2026

On April 23, 2026, MapLight Therapeutics, Inc. directors Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of their decision not to stand for reelection at the Annual Meeting of Stockholders on June 23, 2026. The Board nominated Martin Babler and Troy Cox as Class I director nominees to replace them. Their decisions were not due to any disagreements with the Company regarding operations, policies, or practices.

  • ·Form 8-K filed on April 29, 2026, reporting event dated April 23, 2026.
  • ·Company is an emerging growth company.
  • ·Securities: Voting Common Stock, $0.0001 par value per share (MPLT on Nasdaq Global Select Market).
PLEXUS CORP8-Kmixedmateriality 9/10

29-04-2026

Plexus Corp reported record fiscal Q2 2026 revenue of $1.164 billion, up 19% YoY from $0.980 billion and 9% QoQ from $1.070 billion, with GAAP operating margin of 5.3% and diluted EPS of $1.82, alongside record manufacturing wins of $355 million in annualized revenue. Non-GAAP operating margin reached 6.0% and EPS $2.05, with free cash flow of $16.0 million and ROIC of 13.8%; however, top 10 customers rose to 54% of revenue, increasing concentration risk, and Q3 guidance shows GAAP operating margin declining to 4.1%-4.5% due to higher stock-based compensation. Q3 revenue guidance is $1.200-$1.250 billion (5% sequential growth at midpoint), with non-GAAP EPS of $2.02-$2.18.

  • ·Cash flows from operations Q2 FY26: $28.5 million; capital expenditures: $12.5 million.
  • ·Fiscal 2026 free cash flow expectation: $50-$75 million.
  • ·Weighted average cost of capital FY26: 9.0%.
  • ·Q3 FY26 GAAP operating margin guidance: 4.1%-4.5% (decline from Q2's 5.3%).
Nextpower Inc.8-Kneutralmateriality 7/10

29-04-2026

On April 23, 2026, Bruce Ledesma, Chief Legal and Compliance Officer of Nextpower Inc., informed the company of his retirement effective July 17, 2026, with the company acknowledging his significant contributions. The Board of Directors approved the appointment of Lindsey Wiedmann as the new Chief Legal and Compliance Officer effective upon Mr. Ledesma’s retirement; Ms. Wiedmann has over 15 years of legal experience in the solar industry, most recently as Chief Legal and Sustainability Officer at Maxeon Solar Technologies, Ltd.

  • ·8-K filing dated April 29, 2026, reporting earliest event on April 23, 2026.
  • ·Board approval of Lindsey Wiedmann's appointment on April 28, 2026.
Olema Pharmaceuticals, Inc.8-Kpositivemateriality 7/10

29-04-2026

Olema Pharmaceuticals, Inc. (Nasdaq: OLMA) announced the appointment of Prakash Raman, Ph.D., to its Board of Directors on April 29, 2026. Dr. Raman, current CEO of InduPro Therapeutics with prior leadership at Ribon Therapeutics, Flagship Pioneering, and Novartis, brings over two decades of biopharmaceutical expertise in business development and strategy. The appointment supports Olema's advancement of lead program palazestrant (OP-1250) through two Phase 3 trials including OPERA-01 (pivotal data expected this fall) and OP-3136, a Phase 1 KAT6 inhibitor.

  • ·Dr. Raman served nearly 14 years at Novartis, most recently as Vice President, Global Head of NIBR Business Development and Licensing.
  • ·Dr. Raman has served on the Board of Directors of Black Diamond Therapeutics since April 2024.
  • ·Olema headquartered in San Francisco with operations in Cambridge, Massachusetts.
TriSalus Life Sciences, Inc.8-Kneutralmateriality 5/10

29-04-2026

On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. of her intention to retire as Chief of Clinical Operations, effective October 1, 2026. The company previously announced on April 7, 2026, the appointment of Dr. Richard Marshall as Chief Medical Officer, effective June 29, 2026. No financial or performance impacts from these changes were disclosed.

  • ·Form 8-K filed on April 29, 2026
  • ·Common stock ($0.0001 par value) trades as TLSI on Nasdaq Global Market
  • ·Warrants (exercisable at $11.50 per share) trade as TLSIW on Nasdaq Global Market
Farmers & Merchants Bancshares, Inc.8-Kneutralmateriality 4/10

29-04-2026

On April 28, 2026, the Board of Directors of Farmers and Merchants Bancshares, Inc. amended and restated its 2023 Equity Compensation Plan, authorizing an additional 200,000 shares of common stock and increasing the total authorized shares under the plan to 230,000. The company intends to file a Form S-8 registration statement with the SEC to register these additional shares. Terms of the plan were previously summarized in the company's Form 8-K filed on July 19, 2023.

  • ·Common stock par value $0.01 per share
  • ·Company to file Registration Statement on Form S-8 for the additional shares
XPEL, Inc.8-Kneutralmateriality 4/10

29-04-2026

XPEL, Inc. appointed Mark Thornton to its Board of Directors on April 23, 2026, with his term lasting until the Annual Meeting of Stockholders on June 10, 2026. Mr. Thornton, aged 51 with over 28 years at The Procter & Gamble Company including roles in global quality assurance and leading Pampers in Asia-Pacific, was also appointed to the Compensation and Nominating and Corporate Governance Committees. He will receive standard director indemnification and a prorated $60,000 annual cash retainer, payable in cash or shares at his option.

  • ·Filing signed on April 28, 2026, reporting event of April 23, 2026
  • ·XPEL common stock trades on Nasdaq under symbol XPEL, par value $0.001 per share
FORWARD AIR CORP8-Kneutralmateriality 5/10

29-04-2026

Forward Air Corporation's board received notice on April 24, 2026, from directors Charles L. Anderson and Robert L. Edwards, Jr., designated by Ridgemont Equity Partners under the January 25, 2024 Shareholders Agreement, that they will not stand for re-election at the June 17, 2026 annual meeting. Neither decision resulted from any disagreement with the company on operations, policies, or practices; Ridgemont does not plan to nominate replacements for this meeting but reserves future designation rights. The board will reduce its size from seven to five directors effective immediately following the annual meeting.

  • ·Shareholders Agreement dated January 25, 2024, governs Ridgemont's director designations.
  • ·Mr. Anderson serves on the Board’s Compensation Committee; Mr. Edwards on the Corporate Governance and Nominating Committee.
FMC CORP8-Kneutralmateriality 4/10

29-04-2026

FMC Corporation filed a Certificate of Amendment to its Restated Certificate of Incorporation on April 29, 2026, broadening the corporate purpose to any lawful activity, authorizing 265,000,000 total shares (260,000,000 common shares at $0.10 par value and 5,000,000 preferred shares without par value), and updating governance provisions in Article EIGHTH regarding board size (3-15 directors), powers, by-laws, stockholder meetings, and director liability limitations. The amendments were duly adopted under Delaware law. No financial impacts or performance metrics are disclosed.

  • ·Amendments include no preemptive rights for stockholders and prohibition on stockholder actions by written consent.
  • ·Special stockholder meetings may only be called by the Board of Directors.
  • ·Director liability limitations exclude breaches of loyalty, bad faith, Section 174 violations, or improper benefits.
Twin Hospitality Group Inc.8-Kneutralmateriality 8/10

29-04-2026

FAT Brands Inc. and Twin Hospitality Group Inc. (TWNP) appointed Keshav Lall as interim Chief Executive Officer effective April 29, 2026, filling in for the former CEO on leave of absence during ongoing Chapter 11 bankruptcy proceedings (Case No. 26-90126) commenced January 26, 2026. Mr. Lall, a Founding Partner at Uzzi & Lall with extensive restructuring experience, was engaged pursuant to an Engagement Letter dated April 26, 2026, at a compensation rate of $100,000 per month. No family relationships, arrangements, or related-party transactions exist with Mr. Lall.

  • ·Engagement Letter filed as Exhibit 10.1.
  • ·Mr. Lall previously served as Senior Managing Director at a financial advisory firm, Chairman and CEO of Essar Capital Americas, and held roles at Deutsche Bank, Marblegate, Citadel, and Balyasny.
  • ·Mr. Lall holds a degree from Cornell University in applied economics and business management.
RAMBUS INC8-Kpositivemateriality 8/10

29-04-2026

Rambus Inc. (NASDAQ: RMBS) announced the appointment of Sumeet Gagneja as senior vice president and chief financial officer, effective April 29, 2026. Mr. Gagneja, with over two decades of experience in semiconductor, data center, and AI ecosystems, previously served as divisional CFO for AMD’s Data Center segment and held CFO and senior finance roles at Western Digital, Xilinx, Innovium, Maxim Integrated, Avago, and Intel. Rambus CEO Luc Seraphin highlighted Gagneja's expertise in scaling businesses and driving profitable growth.

  • ·Gagneja holds a Master of Business Administration from University of Michigan Ross School of Business and a master’s degree in mechanical engineering from Wayne State University.
  • ·He is a California Certified Public Accountant.
  • ·Rambus has over three decades of advanced semiconductor experience.
SOUTHERN COPPER CORP/8-Kmixedmateriality 9/10

29-04-2026

Southern Copper Corporation announced the unexpected passing of its President, Chief Executive Officer, and Board member Oscar Gonzalez Rocha on April 13, 2026. On April 23, 2026, the Board of Directors appointed Leonardo Contreras Lerdo de Tejada as the new Chief Executive Officer, who will continue to serve on the Board. No changes to Mr. Contreras Lerdo de Tejada's compensation have been approved in connection with the appointment.

  • ·Biographical information for Mr. Leonardo Contreras Lerdo de Tejada is incorporated by reference from the Company's 2025 Proxy Statement (filed April 11, 2025) and 2026 Proxy Statement (filed April 17, 2026).
  • ·The Company will file a Form 8-K amendment if any material compensatory arrangements are entered into or amended with the new CEO.
FIRST MID BANCSHARES, INC.8-Kpositivemateriality 9/10

29-04-2026

First Mid Bancshares, Inc. (FMBH) announced a planned leadership transition effective July 1, 2026, with Matthew K. Smith, current President, succeeding as CEO and President and joining the Board of Directors, while Joseph R. Dively transitions from Chairman and CEO to Executive Chairman. During Smith's tenure since 2016, the company grew total assets from $2.8 billion to $9.3 billion through strategic initiatives and organic growth. Dively will continue leading M&A strategy and board oversight, ensuring continuity.

  • ·Smith joined in 2016 as CFO, named President in June 2025; CPA with degrees in finance, business administration, accounting.
  • ·Dively CEO since January 1, 2014; Director since 2004.
  • ·Operates in Illinois, Iowa, Missouri, Texas, Wisconsin, and loan production office in Indiana.
  • ·NASDAQ: FMBH
YELP INC8-Kneutralmateriality 6/10

29-04-2026

On April 23, 2026, Sam Eaton notified Yelp Inc. of his decision to step down from his position as Chief Technology Officer, effective June 30, 2026, after more than 13 years with the Company. Alex Levy, the Company’s Senior Vice President, Engineering, has been appointed to serve as Chief Technology Officer following that date. The filing was made on April 29, 2026.

SOLESENCE, INC.8-Kpositivemateriality 6/10

29-04-2026

Solésence, Inc. (Nasdaq: SLSN) announced the appointment of Marc James as a new independent director to its Board of Directors, effective immediately on April 27, 2026. James will serve on the Audit, Compensation, and Nominating Committees, supporting the company's Transform & Transcend strategic initiative and long-term growth. The move is positioned to enhance corporate governance, board expertise in capital markets, and strategic execution.

  • ·Filing date: April 29, 2026
  • ·James has experience in global financial markets, advising on capital markets activities, interest rate risk management, and financing strategies
JACOBS SOLUTIONS INC.8-Kneutralmateriality 4/10

29-04-2026

On April 26, 2026, Diane Bryant resigned as a member of the Board of Directors of Jacobs Solutions Inc. Her decision to resign was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. The Form 8-K was filed on April 29, 2026, and signed by Chasity Henry, EVP, General Counsel & Corporate Secretary.

Kinsale Capital Group, Inc.8-Kpositivemateriality 7/10

29-04-2026

Kinsale Capital Group, Inc. (NYSE: KNSL) announced the realignment of its Analytics and Technology groups under a single leader, promoting Salmaan K. Allibhai to Executive Vice President, Chief Analytics and Technology Officer and Nicholas J. Kunkle to Vice President, Chief Actuary. Diane Schnupp retired as Executive Vice President and Chief Information Officer effective April 29, 2026, but will continue in a consulting role for a smooth transition. The changes aim to eliminate operational silos and enhance data-driven decision-making.

  • ·Salmaan K. Allibhai joined Kinsale in April 2016, previously served as Senior Vice President and Chief Actuary, holds a bachelor’s in Mathematical Decision Sciences and Economics from UNC Chapel Hill, Fellow of Casualty Actuarial Society.
  • ·Nicholas J. Kunkle joined in April 2024 as Senior Actuary, promoted to Managing Actuary in March 2025, holds doctorate in Musical Arts from University of Texas at Austin, Fellow of Casualty Actuarial Society.
  • ·Diane Schnupp led technology strategy for the last seven years.
CITY HOLDING CO8-Kneutralmateriality 6/10

29-04-2026

City Holding Company and City National Bank of West Virginia amended the employment agreement of Charles R. Hageboeck, effective April 29, 2026, relieving him of the President title at City National while he continues as Chief Executive Officer. The amendment removes all references to the President role from the original July 25, 2007 agreement. The document was signed by Chairman C. Dallas Kayser on behalf of both entities.

  • ·Original Employment Agreement effective July 25, 2007.
  • ·Amendment removes all references and inferences to Employee serving as President of City National.

Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 30 filings

More from: US Executive Officer Management Changes SEC

🇺🇸 More from United States

View all →